| abstract |
This application relates to a use of IL-lβ ;-ligand/IL-l receptor disrupting compounds (herein referred to as 'IL-lbeta Compounds') ; such as small molecular compounds disrupting IL-lβ; ligand - IL-I receptor interaction, IL-lβ; antibodies or IL-I receptor antibodies, e.g. IL-lβ; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-lβ; binding compounds or IL-I receptor binding compounds, and/or RNA compounds decreasing either IL-lβ; ligands or IL-I receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans . |